Epoetin Alfa Contraindications in Acute Myeloid Leukemia

Introduction to Epoetin Alfa Contraindications

• The American Society of Hematology recommends that epoetin alfa should not be used in patients with acute myeloid leukemia (AML) due to increased mortality risk and lack of efficacy evidence 1, 2, 3
• The National Comprehensive Cancer Network guidelines state that erythropoiesis-stimulating agents (ESAs) are contraindicated in AML patients, as they increase the risk of death when used in patients with active malignancy not receiving chemotherapy 1, 2

Critical Distinction: AML vs. MDS

• The European Society for Medical Oncology notes that the evidence base for ESAs applies to myelodysplastic syndromes (MDS), not AML, and that these are fundamentally different diseases requiring different management approaches 4, 5, 6
• The American College of Physicians recommends that ESAs are appropriate for lower-risk MDS patients with response rates of 40-60% when serum erythropoietin is <500 mU/L 4, 5

Why Epoetin Alfa is Contraindicated in AML

• The FDA has issued a black-box warning stating that ESAs increase the risk of death when administered to patients with active malignant disease not receiving chemotherapy or radiation therapy 1, 2
• The FDA also states that ESAs are not indicated in patients with cancer-related anemia who are not receiving concurrent myelosuppressive chemotherapy 2
• There is no published high-quality evidence supporting epoetin alfa use in AML, and all ESA studies in hematologic malignancies excluded AML patients or focused on MDS 1, 2

Appropriate Anemia Management in AML

• The National Comprehensive Cancer Network recommends red blood cell transfusions to maintain hemoglobin levels adequate for symptoms and quality of life in patients with active AML 3, 4
• The American Society of Clinical Oncology suggests transfusing to keep hemoglobin >7-8 g/dL or higher if symptomatic 7
• The European Society for Medical Oncology recommends addressing underlying leukemia with appropriate chemotherapy (intensive or palliative) 3

Common Pitfall to Avoid

• The American College of Physicians warns against extrapolating MDS data to AML patients, as ESAs work in lower-risk MDS but not in AML 4, 5, 6
• If a patient with MDS on ESAs progresses to AML, ESAs must be discontinued immediately 4, 6
• The presence of ≥20% blasts in bone marrow or peripheral blood defines AML and represents an absolute contraindication to ESA therapy 1